BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Chemistry & Biochemistry - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:/chemistry
X-WR-CALDESC:Events for Chemistry & Biochemistry
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260306T150000
DTEND;TZID=America/Chicago:20260306T160000
DTSTAMP:20260417T123926
CREATED:20260202T170833Z
LAST-MODIFIED:20260202T170833Z
UID:10003972-1772809200-1772812800@uwm.edu
SUMMARY:Colloquium\, Guest Speakers Kevin Patterson & Ashley Bayer\, Milwaukee Metropolitan Sewerage District
DESCRIPTION:
URL:/chemistry/event/colloquium-guest-speakers-kevin-patterson-ashley-bayer-milwaukee-metropolitan-sewerage-district/
LOCATION:Chemistry Lecture Hall 110\, 2000 E. Kenwood Boulevard\, Milwaukee\, WI\, 53211\, United States
CATEGORIES:Colloquium
X-TRIBE-STATUS:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260313T150000
DTEND;TZID=America/Chicago:20260313T160000
DTSTAMP:20260417T123926
CREATED:20260202T170951Z
LAST-MODIFIED:20260309T152028Z
UID:10003973-1773414000-1773417600@uwm.edu
SUMMARY:Colloquium\, Mayurika Mahendran\, 51ÁÔĆć Chemistry
DESCRIPTION:Chemical Perspectives on Therapeutic Challenges and Emerging Treatment Strategies for Triple-Negative Breast Cancer (TNBC)\n\n\nTriple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer characterized by the absence of Estrogen receptor (ER)\, Progesterone receptor (PR)\, and HER2 expression. TNBC accounts for approximately 15–20% of all breast cancers and is associated with early metastasis\, high recurrence rates\, and poor prognosis. Because TNBC lacks targetable hormone receptors\, conventional chemotherapy remains the backbone of treatment. Common agents such as Paclitaxel\, Doxorubicin\, and Carboplatin exert their therapeutic effects through mechanisms including microtubule stabilization\, DNA intercalation\, Topoisomerase inhibition\, and DNA crosslinking. Although these cytotoxic mechanisms are effective\, systemic toxicity\, chemo resistance\, tumor heterogeneity\, and radio resistance limit long-term therapeutic success.\n\n\nRecent advances have expanded the TNBC treatment landscape through immunotherapy and targeted approaches. Immune checkpoint inhibitors\, particularly PD-1/PD-L1 blockers such as Pembrolizumab\, enhance T-cell–mediated tumor recognition and have demonstrated improved pathological complete response (pCR) and overall survival (OS) when combined with chemotherapy. Additionally\, PARP inhibitors exploit synthetic lethality in BRCA-mutated TNBC by impairing DNA repair pathways\, promoting tumor cell death.\nAnother promising strategy involves antibody-drug conjugates (ADCs)\, such as Sacituzumab Govitecan (SG)\, which combine monoclonal antibody specificity with potent cytotoxic payloads through cleavable linker chemistry\, enabling selective intracellular drug release.\n\n\n\nCombination therapeutic strategies are emerging as a critical direction in TNBC management. Integrating chemotherapy\, immunotherapy\, radiotherapy\, and targeted agents has demonstrated improved progression-free survival (PFS)\, overall response rate (ORR)\, and overall survival (OS) compared to monotherapy. From a chemical perspective\, rational drug design\, linker optimization\, and molecular targeting strategies play central roles in improving selectivity\, overcoming resistance mechanisms\, and reducing systemic toxicity. Continued advancements in immunology\, nanotechnology\, and molecular biology are expected to facilitate personalized and more effective treatment strategies for TNBC.
URL:/chemistry/event/colloquium-mayurika-mahendran-uwm-chemistry/
LOCATION:Chemistry Lecture Hall 110\, 2000 E. Kenwood Boulevard\, Milwaukee\, WI\, 53211\, United States
CATEGORIES:Colloquium
X-TRIBE-STATUS:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260320T150000
DTEND;TZID=America/Chicago:20260320T160000
DTSTAMP:20260417T123926
CREATED:20260202T171049Z
LAST-MODIFIED:20260313T150258Z
UID:10003974-1774018800-1774022400@uwm.edu
SUMMARY:Guest Speaker\, Regan Thomson\, Ph.D.\, Northwestern University
DESCRIPTION:Natural Products in the Atmosphere\n\nVolatile terpenes emitted from the world’s forests play a significant role in the formation of atmospheric aerosol particles\, which in turn influence climate\, air quality\, and human health through a variety of direct and indirect mechanisms. Despite the importance of these aerosol particles\, they remain poorly understood and constitute the largest degree of uncertainty in climate models. Recent studies have also led to the development of a novel biosphere–atmosphere feedback loop hypothesis whereby plants may be altering the emission of biogenic terpenes to enhance rainfall during drought conditions. This lecture will describe efforts within my lab towards the synthesis of putative biogenic terpene-derived constituents of atmospheric aerosol particles in order to confirm their identities and explore their climate relevant physical properties. Recent advances in the synthesis of isotopically-labeled pinene derivatives that are driving collaborative investigations into the complex oxidation pathways of terpenes in the atmosphere will also be presented along with ongoing efforts exploring the role of chirality in the atmosphere.\n\nRegan J. Thomson was born in New Zealand in 1976\, and received his Ph.D. in 2003 at The Australian National University where he worked for Prof. Lewis N. Mander. Following postdoctoral studies at Harvard University with Prof. David A. Evans\, he joined the faculty at Northwestern University in 2006 where he is currently a Professor of Chemistry. Regan’s research interests include natural product synthesis and discovery\, and atmospheric chemistry. He is the recipient of an NSF CAREER Award\, an Amgen Young Investigator Award\, a Novartis Lectureship\, and an Illinois Division American Cancer Society Research Scholar Award. At Northwestern he has been named a Charles Deering Professor of Teaching Excellence and awarded the Provost Award for Exemplary Faculty Service.
URL:/chemistry/event/guest-speaker-regan-thomson/
LOCATION:Chemistry Lecture Hall 110\, 2000 E. Kenwood Boulevard\, Milwaukee\, WI\, 53211\, United States
CATEGORIES:Colloquium
X-TRIBE-STATUS:
END:VEVENT
END:VCALENDAR